The journey of targeted drug conjugates in solid tumors: moving beyond antibody drug conjugates

Expert Opinion on Investigational Drugs · Published 2026-06-03 · DOI 10.1080/13543784.2026.2683842

Free full text

Authors (4)

Stephen J. Walsh, Francesca Wood, Leslie R. DeMars, Gavin Bennett

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Walsh, S., Wood, F., DeMars, L., et al. (2026). The journey of targeted drug conjugates in solid tumors: moving beyond antibody drug conjugates. Expert Opinion on Investigational Drugs. https://doi.org/10.1080/13543784.2026.2683842

Related articles

• Advancements in longevity pharmacology research – are we finally seeing clinical progression? · Expert Opinion on Investigational Drugs · 2026 · Same journal
• Placebo-controlled trial of pharmacokinetics, pharmacodynamics and tolerability of KL130008 capsule in patients with rheumatoid arthritis · Expert Opinion on Investigational Drugs · 2025 · Same journal
• Assessing the clinical development of zerlasiran, a small-interfering RNA for elevated lipoprotein(a) · Expert Opinion on Investigational Drugs · 2025 · Same journal
• Cognitive-enhancing drugs in Phase II clinical trials for Alzheimer’s disease: emerging therapeutic candidates · Expert Opinion on Investigational Drugs · 2026 · Same journal
• Assessing the clinical progress of muvalaplin for reducing lipoprotein(a) · Expert Opinion on Investigational Drugs · 2025 · Same journal
• Menin inhibitors for adult acute myeloid leukemia: 2025 update · Expert Opinion on Investigational Drugs · 2025 · Same journal
• Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much? · Expert Opinion on Investigational Drugs · 2026 · Same journal
• Experimental JAK inhibitors: the current, present, and future in graft-versus-host disease management? · Expert Opinion on Investigational Drugs · 2026 · Same journal
• A randomized, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and ammonia-lowering effect of Rifaquizinone, an intestinally restricted investigational drug · Expert Opinion on Investigational Drugs · 2026 · Same journal
• Potential of IMNN-001 in epithelial ovarian cancer: assessment of clinical findings · Expert Opinion on Investigational Drugs · 2026 · Same journal